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ABSTRACT
Adipose tissue is an ideal source of mesenchymal stem cells for bone tissue engineering: it is
largely dispensable and readily accessible with minimal morbidity. However, the stromal vas-
cular fraction (SVF) of adipose tissue is a heterogeneous cell population, which leads to unreli-
able bone formation. In the present study, we prospectively purified human perivascular stem
cells (PSCs) from adipose tissue and compared their bone-forming capacity with that of tradi-
tionally derived SVF. PSCs are a population (sorted by fluorescence-activated cell sorting) of
pericytes (CD146CD34−CD45−) and adventitial cells (CD146−CD34CD45−), each of which we
have previously reported to have properties of mesenchymal stem cells. Here, we found that
PSCs underwent osteogenic differentiation in vitro and formed bone after intramuscular im-
plantation without the need for predifferentiation. We next sought to optimize PSCs for in vivo
bone formation, adopting a demineralized bone matrix for osteoinduction and tricalcium phos-
phate particle formulation for protein release. Patient-matched, purified PSCs formed signifi-
cantly more bone in comparison with traditionally derived SVF by all parameters. Recombinant
bone morphogenetic protein 2 increased in vivo bone formation but with a massive adipogenic
response. In contrast, recombinant Nel-like molecule 1 (NELL-1; a novel osteoinductive growth
factor) selectively enhanced bone formation. These studies suggest that adipose-derived hu-
man PSCs are a new cell source for future efforts in skeletal regenerative medicine. Moreover,
PSCs are a stem cell-based therapeutic that is readily approvable by the U.S. Food and Drug
Administration, with potentially increased safety, purity, identity, potency, and efficacy. Fi-
nally, NELL-1 is a candidate growth factor able to induce human PSC osteogenesis. STEMCELLS
TRANSLATIONAL MEDICINE 2012;1:510–519
INTRODUCTION
Since the original description of adipose tissue as
a source of adult multilineage stem cells [1], the
preclinical study of adipose-derived cells for re-
pair and regeneration of tissues has increased
dramatically (reviewed in [2]). The theoretical
advantages of adipose-derived cells over other
cell types for biologic bone regeneration strate-
gies are numerous. For example, although au-
tograft bone remains the gold standard for bone
repair, its disadvantages are significant, including
donor site morbidity, extended operating time
complications, and limited autogenous supply
[3–5]. On the other hand, bone marrow mesen-
chymal stem cells (BMSCs) have long been stud-
ied for their application to skeletal engineering.
However, BMSCs have distinct disadvantages
over adipose-derived cells, including limitations
in autogenous supply of bonemarrowaspirate as
compared with lipoaspirate, and relatively lower
cell yield of BMSCs in comparison with adipose-
derived stem cells (ASCs) (estimated at 104
stem cells vs. 106 stem cells per 40 ml) [6–8].
Finally, human ASCs have been used successfully
to heal small animal [9, 10] and large animal [11]
skeletal defects.
Despite the advantages of fat tissue-derived
cells for bone regeneration, there exist clear hur-
dles that must be overcome for their successful
clinical use. For example, adipose-derived stro-
mal cells are defined by their adherence to cell
culture plates and ex vivo expansion. This ex vivo
expansion increases the risk of immunogenicity,
infection, and genetic instability [12, 13]. As an
alternative to ASCs, the cells of noncultured total
stromal vascular fraction (SVF) from adipose tis-
sues have been used. Available studies using SVF
show poor and unreliable bone formation [14] or
lower bone regeneration efficacy relative to cul-
tured ASCs [15]. SVF of adipose tissue is a highly
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heterogeneous cell population, including nonmesenchymal
stem cell types, such as inflammatory cells, hematopoietic stem
cells, and endothelial cells, among others [16]. Variability in cell
composition presents clear disadvantages forU.S. Food andDrug
Administration (FDA) approval of a future stem cell-based ther-
apeutic, potentially including reduced safety, purity, identity, po-
tency, and efficacy. Notably, these are the criteria upon which
the Center for Biologics Evaluation and Research evaluates stem
cell-based product applications [17]. For example, given the het-
erogeneity of SVF, precise product characterization is not feasi-
ble, leading to lack of human stromal vascular fraction (hSVF)
product identity. Batch-to-batch variability and nonuniformity in
effect (again attributable to variable stem cell content) reduces
the efficacy and potency of hSVF compounds and potentially
reduces product safety. With these regulatory hurdles in mind,
our approach was to reduce the inherent heterogeneity within
hSVF to obtain a safer andmore efficacious stem cell-based ther-
apeutic.
To address this issue of SVF heterogeneity, previous investi-
gators have used fluorescence-activated cell sorting (FACS) to
purify fat-derived cell populations, with some success. For exam-
ple, cell sorting of adipose tissue has allowed for enrichment of
osteoprogenitor [18] or chondroprogenitor [19] cell types—but
not the isolation ofmultipotentmesenchymal stem cells (MSCs).
Our solution has been to identify the native perivascular pheno-
type of MSCs and prospectively isolate perivascular MSCs using
multicolor FACS. We have previously shown two populations of
perivascular stem cells (PSCs) associated with blood vessels
[20–24]. These include CD34CD146CD45 pericytes sur-
rounding microvessels and capillaries [20, 25] and a second dis-
tinct adventitial cell (CD34CD146CD45) [26], associated
with larger blood vessels. Both cell types are isolatable from ad-
ipose tissue and resembleMSCs bymorphology, growth, surface
markers, and clonal multilineage differentiation potential
[20–24].
In this report, we describe the use of a novel, FACS-purified
cell source for improved bone tissue engineering: human
perivascular stem cells (hPSCs). Using an intramuscular, ectopic
bone model, we observed that adipose-derived, FACS-isolated
hPSCs formed bone to a greater degree than patient-matched,
unsorted hSVF. Next, two growth factors were examined for
their osteoinductive effects: bone morphogenetic protein 2
(BMP2) and Nel-like molecule-1 (NELL-1). The novel cytokine
NELL-1 was identified as an appropriate osteogenic stimulus
rather than BMP2, which had pleiotropic effects, including adi-
pogenic differentiation and cyst-like bone formation.
MATERIALS AND METHODS
Isolation of SVF from Human Lipoaspirate
Human lipoaspirate (n 70 donors) was obtained from patients
undergoing cosmetic liposuction. No patient identifiers were ob-
tained. Lipoaspirate was stored for no more than 128 hours at
4°C before processing. The hSVF was obtained by collagenase
digestion as previously described [26]. Briefly, lipoaspirate was
dilutedwith an equal volume of phosphate-buffered saline (PBS)
before digestion with Dulbecco’s modified Eagle’s medium
(DMEM) containing 3.5% bovine serum albumin (Sigma-Aldrich,
St. Louis, http://www.sigmaaldrich.com) and 1mg/ml type II col-
lagenase for 70 minutes under agitation at 37°C. Next, adi-
pocyteswere separated and removed by centrifugation. The pel-
let was then resuspended in red-cell lysis buffer (155mMNH4Cl,
10 mM KHCO3, and 0.1 mM EDTA) and incubated for 10 minutes
at room temperature. After centrifugation, pellets were resus-
pended in PBS and filtered at 70 m. The resulting hSVF was
either further processed for cell sorting (to isolate PSCs) or used
immediately for in vivo application. In order to calculate live cell
number for implantation, trypan blue staining was performed to
assess cell viability. Cells were kept on ice until in vivo implanta-
tion. n 70 patient samples were used for in vitro experiments,
and n  6 patient samples were used for in vivo experiments;
demographics were recorded, including age, sex, and anatomic
location of harvest, and are presented in supplemental online
Table 1.
Purification of PSCs from Human Lipoaspirate
PSCs were purified by FACS of the hSVF as previously described
[26]. hSVF was incubated with amixture of the following directly
conjugated antibodies: anti-CD34-phycoerythrin (1:100; Dako,
Glostrup, Denmark, http://www.dako.com), anti-CD45-allophy-
cocyanin (1:100; Santa Cruz Biotechnology Inc., Santa Cruz, CA,
http://www.scbt.com), and anti-CD146-fluorescein isothiocya-
nate (1:100; AbD Serotec, Raleigh, NC, http://www.ab-direct.
com). All incubations were performed at 4°C for 15 minutes in
the dark. Before sorting, 4,6-diamidino-2-phenylindole (DAPI;
1:1,000; Invitrogen, Carlsbad, CA, http://www.invitrogen.com)
was added for dead cell exclusion; the solution was then passed
through a 70-mcell filter and then run on a FACSAria cell sorter
(BD Biosciences, San Diego, CA, http://www.bdbiosciences.
com). Sorted cells were used for in vivo application immediately
or plated for in vitro studies. In this manner, distinct microvessel
pericytes (CD34, CD146, CD45) and adventitial cells
(CD34, CD146, CD45) were isolated and combined to con-
stitute the PSC population. For select experiments, fluorescent
labeling of live cells was performed prior to implantation using
PKH26 fluorescent cell linker (Sigma-Aldrich). Cells were kept on
ice until in vivo implantation.
In Vitro Assays
The expansion of cells was performed in DMEM, 20% fetal bo-
vine serum (FBS), 1% penicillin/streptomycin. Osteogenic differ-
entiation of human PSCs was performed as previously described
[9, 27], withminormodifications. Passage 4 PSCs were seeded at
a density of 35,000 cells perwell in 12-well plates. Differentiation
medium consisted of DMEM, 10% FBS, 100 g/ml ascorbic acid,
and 10mM-glycerophosphate. Assessments, including alkaline
phosphatase and alizarin red staining, were performed as previ-
ously described [10, 28].
Implant Preparation
Implants were prepared as per supplemental online Tables 2–5.
Two different scaffolds were used for cell delivery. First, an ab-
sorbable collagen sponge of defined dimensions (0.5 1 1.5
cm) (component of the INFUSE Bone Graft; Medtronic, Minne-
apolis, MN, http://www.medtronic.com) was used (data pre-
sented in Fig. 1). This carrier was chosen as a nonosteoinductive
carrier, as intramuscular implantation of absorbable collagen
sponge alone is known to have no bone forming effects [29].
Second, an ovine DBX Putty was used (100 l; Musculoskeletal
Transplant Foundation, Edison, NJ, http://www.mtf.org). DBX
Putty combines morselized cortical-cancellous demineralized
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bone chips with sodium hyaluronate, and it was chosen for its
proven osteoinductive characteristics and clinical translation
(human demineralized bone matrix [DBX] is already 510(k)
approved) (data presented in Figs. 2–5). Select experiments
added growth factors (recombinant human BMP2 or NELL-1),
which were lyophilized onto tricalcium phosphate (-TCP)
particles (Chronos -TCP granules, 200–300 m diameter;
Synthes, West Chester, PA, http://www.synthes.com) and
stored at 4°C prior to use. This avoids burst-type release ki-
netics in favor of sustained growth factor release [30]. Con-
centrations of BMP2 were based on the clinical-range doses
needed for human bone formation (up to 1,500 g/ml) rather
than the lower doses more commonly used in mice [31]. Con-
centrations of NELL-1 were based on our previous publication
using an intramuscular model and fetal pancreatic pericytes
[32]. The individual components (DBX  -TCP) were mixed
mechanically prior to implantation. Finally, defined numbers
of viable cells in PBS suspension (20 l) from the hSVF or PSCs
were applied (either allowed to soak into absorbable collagen
sponge or mechanically mixed with DBX/-TCP). The cell 
scaffold suspension was kept on ice until implantation.
Surgical Procedures
Intramuscular implantation was performed in 8-week-old male
SCID mice. Animals were anesthetized by isoflurane inhalation
(5% induction, 2% maintenance) and premedicated with 0.05
mg/kg buprenorphine. Bilateral incisions in the hind limbs were
made, and pockets were cut in the biceps femoris muscles by
blunt dissection, parallel to the muscle fiber long axis. Implants
were placed bilaterally; implant compositions are fully described
in supplemental online Tables 2–6. Numbers of animals per ex-
periment can be found in the figure legends. The fasciae overly-
ing the muscle were sutured with a simple continuous pattern,
and the skin was closed in a separate layer using 5-0 Vicryl (Ethi-
con, San Angelo, TX, http://www.ecatalog.ethicon.com) sutures
in a subcuticular pattern. Animals were postoperatively treated
with buprenorphine for 48 hours and trimethoprim/sulfame-
thoxazole for 10 days for pain management and infection pre-
vention, respectively. Animals were housed and experiments
were performed in accordance with guidelines of the Chan-
cellor’s Animal Research Committee of the Office for Protec-
tion of Research Subjects at the University of California, Los
Angeles.
Radiographic Imaging: High-Resolution XR and
Quantitative Microcomputed Tomography Analysis
Live high-resolution radiographs were taken every 2 weeks for
select experiments using a cabinet radiography system (Faxitron
Bioptics, Lincolnshire, IL, http://www.faxitron.com). Mice were
anesthetized using isoflurane (5% induction, 2% maintenance).
Samples were harvested en bloc from 4 to 6 weeks postim-
plantation, formalin-fixed, and imaged using high-resolution mi-
crocomputed tomography (microCT) (Skyscan 1172F; Skyscan,
Kontich, Belgium, http://www.skyscan.be) at an image resolu-
tion of 19.73 m and analyzed using DataViewer, Recon, CTAn,
and CTVol programs provided by the manufacturer. For com-
puted tomography (CT) data analysis, the region of interest in-
cludes the entire volume of the scannedmuscle pouch excluding
the native femur to quantify bone volume (BV) and bonemineral
density (BMD). Threshold values for three-dimensional recon-
structions and quantification can be found in the figure legends.
All quantitative and structural morphometric data use nomen-
clature described by the American Society for Bone and Mineral
Research Nomenclature Committee [33].
Histology and Immunohistochemistry Analysis
After CT analysis, samples were decalcified in 19% EDTA and
embedded in paraffin. Hematoxylin andeosin (H&E) andMovat’s
pentachrome staining were performed as previously described
[32]. For select experiments, bone formation was quantified by
blinded histomorphometric analyses using H&E staining (Figs. 2,
6) and Photoshop (Adobe Systems Inc., San Jose, CA, http://
Figure 1. Human perivascular stem cells (hPSCs) are an osteocompetent cell population. (A, B): hPSCs were cultured under osteogenic
conditions (10% fetal bovine serum, 100g/ml ascorbic acid, 10mM-glycerophosphate). (A):Representative image of alkaline phosphatase
staining at 5 days of differentiation. (B): Representative image of alizarin red staining, 10 days of differentiation. (C–F): hPSCs were implanted
in the thigh complex of a SCID mouse using a collagen sponge carrier (2.5 105 cells, sponge size 2.0 1.0 0.5 cm). (C): High-resolution
radiography at 2 and 4 weeks postimplantation. (D): Three-dimensional microcomputed tomography reconstructions at threshold 90. (E, F):
Pentachrome staining of histological sections. n 5 implants, from n 1 patient specimens. See supplemental online Table 2 for treatment
groups. Abbreviations: cb, cortical bone; eb, ectopic bone; m, muscle.
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www.adobe.com) quantification as expressed by mean bone
area and bone area/tissue area [34]. For select experiments, ad-
ipogenesis was quantified by blinded calculations of lipid droplet
number per 100 field (Fig. 4). Immunohistochemistry was
performed with primary antibodies against bone sialoprotein
(Chemicon, Temecula, CA, http://www.chemicon.com), osteo-
calcin (Santa Cruz Biotechnology), and major histocompatibility
complex (MHC) class I surface antigen (Santa Cruz Biotechnol-
ogy) using the ABC (Vector Laboratories, Burlingame, CA, http://
www.vectorlabs.com)method. Select quantification of immuno-
histochemistry was performed again using the magic wand tool
in Photoshop with a tolerance setting of 30 (Fig. 2).
Statistical Analysis
Statistical analysis was performed using an appropriate analysis
of variance test when more than two groups were compared,
Figure 2. hPSCs undergomore robust differentiation in comparison with hSVF. Equal numbers of viable hSVF cells or hPSCs (2.5 105) from
the same patient samples were implanted intramuscularly in the thigh of a SCID mouse. An osteoinductive DBX Putty was used as scaffold.
Assessments were performed at 4 weeks postimplantation. (A, B):Microcomputed tomography (microCT) images of hSVF- and hPSC-treated
samples. Representative three-dimensional microCT reconstructions at threshold (Th) 90 (left) and corresponding two-dimensional axial
slices (right). (C, D): Analysis of BV and BMD among hSVF- and hPSC-treated samples; Th50–120. (E): Representative hematoxylin and eosin
staining. (F): Representative histomorphometric quantification of bone area per 100 field. (G): Representative BSP immunohisto-
chemistry. (H): Quantification of relative staining per400 field. (I): Representative OCN immunohistochemistry. (J): Quantification of
relative staining per400 field. Histomorphometric quantification calculated from n 6 randommicroscopical fields. n 12 implants
per cell type, n 3 patient specimens. See supplemental online Table 3 for treatment groups. , p .05 in comparison with control as
assessed by Student’s t test. Abbreviations: BMD, bone mineral density; BSP, bone sialoprotein; BV, bone volume; eb, ectopic bone; f,
femur; hPSC, human perivascular stem cell; hSVF, human stromal vascular fraction; OCN, osteocalcin.
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followed by Student’s t test to compare two groups. Inequality of
SDs was excluded by using Levene’s test. p .05 was considered
to be significant.
RESULTS
Stromal Vascular Fraction of Human White Adipose
Tissue Contains Two Distinct Perivascular MSC
Populations: Pericytes and Adventitial Cells
We recently described, purified, and characterized two perivas-
cular sources of primary MSCs within human adipose tissue
basedon the expression of CD34 andCD146. Pericytes,which are
surrounding microvessels, are isolatable from multiple human
organs, including adipose tissue, and are CD146CD34CD45
[20, 25]. More recently, we have described a second and dis-
tinct perivascular MSC population, adventitial cells
(CD146CD34CD45) [26], obtainable from human adipose
among other tissues. Here, we first confirmed our previous re-
sults, showing that pericytes (CD146CD34) and adventitial
cells (CD146CD34) are distinct populations isolatable from
human lipoaspirate after exclusion of CD45 cells (hematopoi-
etic cells) and DAPI cells (dead cells) (Fig. 6). Both pericytes and
adventitial cells have been previously reported to undergo mul-
tiple mesodermal lineage differentiation [20, 26]. With n  70
unique samples of lipoaspirate, we observed the mean preva-
lence of pericytes and adventitial cells to be 17.1% and 22.5% of
the total viable cell yield of SVF. From a tissue-engineering
standpoint, maximal MSC yield per unit of autologous tissue re-
moved would improve efficacy for tissue engineering while re-
ducing harvest morbidity. For this reason, we chose to combine
both perivascular MSC populations—collectively termed
PSCs—to maximize cell yield for our efforts in bone engineering
(collectively, PSCs make up, on average, 39.6% of total viable
SVF). Importantly, those cells within adipose tissue that are
neither pericytes (CD146CD34) nor adventitial cells
(CD146CD34) do not express typical MSC markers or un-
dergo mesodermal lineage differentiation [26].
Perivascular Stem Cells Undergo Osteogenic
Differentiation In Vitro and Form Bone In Vivo
hPSCswere first evaluated for their ability to undergo osteogenic
differentiation in vitro and bone forming potential in vivo (Fig. 1).
In standard osteogenic medium, hPSCs showed robust alkaline
phosphatase staining after 5 days in differentiation medium and
bone nodule formation after 10 days in differentiation medium
(Fig. 1A, 1B). Freshly derived hPSCs were next placed on a colla-
gen sponge without predifferentiation or growth factor stimula-
tion and inserted intramuscularly (see supplemental online Ta-
ble 2 for treatment groups). Over the course of 6 weeks,
spontaneous mineralization was observed by radiography
(Fig. 1C), three-dimensional CT (Fig. 1D), and histology (Fig. 1E,
1F). In contrast, intramuscular implantation of absorbable colla-
gen sponge alone is known to have no bone forming effects [29].
Collectively, these studies showed that hPSCs (like their individ-
ual pericyte and adventitial components) undergo osteogenic
differentiation in vitro and in vivo and thus may be useful as a
purified cell source for bone formation.
Human PSCs Undergo More Robust Bone Formation
than hSVF Cells
Having demonstrated that hPSCs are an osteocompetent cell
source, we next sought to directly compare bone formation in
patient-matched, purified hPSCs to unsorted hSVF. For this head-
to-head determination, the same numbers of viable hSVF cells or
hPSCs were implanted (2.5  105) intramuscularly. An osteoin-
ductive carrierwas used: demineralized bonematrix (DBXPutty),
which consists of morselized cortical-cancellous demineralized
bone chips with sodium hyaluronate (Musculoskeletal Trans-
plant Foundation) (see supplemental online Table 3 for treat-
ment groups). At 4 weeks postimplantation, two- and three-di-
mensional CT images showed significantly increased bone
formation in hPSC in comparison to hSVF samples (Fig. 2A, 2B).
CT quantification demonstrated a statistically significant in-
crease in BV and BMD in hPSC-treated samples (Fig. 2C, 2D).
Histologic analysis was performed by routine H&E (Fig. 2E).
Histomorphometric quantification of bone area per random
high-powered field showed increased bone among hPSC-treated
samples (Fig. 2F). Immunohistochemical staining for the bone-
specific markers bone sialoprotein and osteocalcin was per-
formed (Fig. 2G, 2I). In each instance, photographic quantitation
of positive staining intensity showed a significant increase in
both bone markers in hPSC-treated specimens (Fig. 2H, 2J). Im-
portantly, we confirmed that those cells surrounding and inter-
spersed between bone chips were of predominantly human ori-
gin (Fig. 3), using immunohistochemical staining for MHC class I
human surface antigen (Fig. 3A) or via fluorescent labeling of
hSVF cells or hPSCs prior to implantation (Fig. 3B). Thus, equiva-
lent numbers of purified hPSCs result in increased ectopic bone
formation in comparison with patient-matched hSVF cells.
Figure 3. Persistence of hSVF or hPSCs
after implantation. Shown are hSVF- or
hPSC-treated samples implanted intra-
muscularly on a DBX Putty scaffold and
assessed for cell persistence 4 weeks
postimplantation. (A): Human major
histocompatibility complex class I im-
munohistochemistry, indicating the pre-
sence of human xenografted cells. (B):
Fluorescent cell labeling (PKH) per-
formed prior to implantation. Red indi-
cates persistence of human cells, and
Hoechst nuclear counterstain appears
blue. Abbreviations: hPSC, human peri-
vascular stem cell; hSVF, human stromal
vascular fraction.
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Having demonstrated that equal numbers of hPSCs form in-
creased bone as compared with hSVF, we next asked as to
whether this difference could be overcome by simply adding
more hSVF cells. For this purpose, two concentrations of cells
were used in the same intramuscular model: either 2.5 104 or
2.5  105 cells per implant. All hSVF or hPSC samples were pa-
tient-matched. If reduced MSC numbers were the only differ-
ence between hSVF and hPSC, then increasing the hSVF cell num-
ber 10-fold would surely mitigate any observed differences.
However, we found this not to be the case (supplemental online
Fig. 1). Namely, hPSCs formed greater bone irrespective of cell
Figure 4. Effects of BMP2 on hSVF- or hPSC-mediated ectopic bone
formation. hSVF or hPSCswere implanted intramuscularlywith orwith-
out BMP2 on a DBX Putty (DBX) scaffold and assessed 4 weeks postim-
plantation. See supplemental online Table 5 for treatment groups.
(A, B): Colorized representative two-dimensional axial microcomputed
tomography images. A scale bar below indicates colorization at various
thresholds. (C):Relative BV. Values are normalized to hSVFDBXonly.
Threshold 100 was used. (D): Relative BMD. Values are normalized to
hSVF DBX only. (E, F): Representative hematoxylin and eosin images
at low (E) and high (F)magnifications. n 8 implants per cell type, n
1 patient specimen. (G): Relative lipid droplet number per100 field.
Meanswere calculated from10 randommicroscopic fields.,p .05 in
comparisonwith hSVF control; #, p .05 in comparisonwith hPSC con-
trol; , p .05 in comparisonwith hSVFwith same dose of BMP2. See
supplementalonlineTable4 for treatmentgroups.Abbreviations:BMD,
bonemineral density; BMP,bonemorphogenetic protein; BV, bonevol-
ume; cs, cortical shell; eb, ectopic bone; f, femur; hPSC, human perivas-
cular stem cell; hSVF, human stromal vascular fraction.
Figure 5. Effects of NELL-1 on hPSC- or hSVF-mediated ectopic bone
formation. hSVF or hPSCs in a SCID mouse muscle pouch with DBX
Putty,with orwithoutNELL-1, assessed at 4weeks postimplantation.
See supplemental online Table 6 for treatment groups. (A): Repre-
sentative three-dimensional microcomputed tomography (microCT)
reconstructions. Threshold (Th) 90 was used. (B): Colorized repre-
sentative two-dimensional microCT images. A scale bar below indi-
cates colorization at various thresholds. (C): Relative BV; Th50–120
used. (D): Relative BMD. (E, F): Representative hematoxylin and eo-
sin staining at low (E) and high (F)magnifications. (G, H): Histomor-
phometric analysis of mean bone area (G) and mean bone area/
tissue area (H), as calculated from 30 random high-powered-fields.
n 9 implants per treatment group, n 1 patient specimen. , p
.05 in comparison with hSVF control; #, p .05 in comparison with
hPSC control; , p  .05 in comparison with hSVF with same dose
NELL-1. See supplemental online Table 5 for treatment groups. Ab-
breviations: BMD, bone mineral density; BV, bone volume; hPSC,
human perivascular stem cell; hSVF, human stromal vascular frac-
tion; NELL-1, Nel-like molecule 1.
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concentration than hSVF. This was observed by microCT recon-
structions of representative samples (supplemental online
Fig. 1A), microCT quantifications of BV and BMD (supplemental
online Fig. 1B, 1C), and representative histological fields (supple-
mental online Fig. 1D, 1E). Thus, a simple reduction in stem cell
number likely does not explain the difference in bone formation
between hSVF and purified hPSC.
BMP2 Promotes hPSC Osteogenic and Adipogenic
Differentiation
Themost commonly used growth factor for bone regeneration is
BMP2 (INFUSE Bone Graft) [35]. We next sought to determine
whether BMP2 would be an appropriate stimulus for hPSC bone
formation (see supplemental online Table 4 for treatment
groups). Two-dimensional axial CT scans showed a clear increase
in bone formation among both hSVF- and hPSC-treated samples
in response to BMP2 (Fig. 4A, 4B). In addition, a striking trend
was observed in which a thin cortical shell (indicated by white
arrows in Fig. 4A) was observed in BMP2-treated specimens that
extended well beyond the usual ectopic bone margins (Fig. 4A,
4B). Quantification of BV and BMD were next performed with
BMP2-treated specimens. First, we again found that BV andBMD
were increased in hPSC as compared with hSVF-treated samples
(Fig. 4C, 4D, far left). However, the effects of BMP2were to some
extent unexpected. Although BMP2 produced a significant in-
crease in BV (Fig. 4C), it had a negative and opposing effect on
BMD as comparedwith hSVF or hPSC alone (Fig. 4D). Histological
evaluation was more revealing (Fig. 4E, 4F). In hSVF and hPSC
sampleswithout BMP2, bone chipswere closer together (Fig. 4E)
and were interspersed with cells with fibroblastic morphology
(Fig. 4F, left). In BMP2-treated hSVF or hPSC samples, however,
bone chips were farther apart and predominantly interspersed
with lipid droplets (Fig. 4F). In order to quantify the adipogenic
response produced by BMP2, relative lipid droplet number per
100 fieldwas determined.Within both hSVF- and hPSC-treated
samples, BMP2 induced a statistically significant increase in lipid
droplet number (Fig. 4G). Thus, BMP2 had both pro-osteogenic
and also proadipogenic effects within both hSVF- and hPSC-
treated implants and may not be the most appropriate cytokine
stimulus for induction of hPSC-mediated high-quality bone for-
mation.
NELL-1 Promotes hPSC Osteogenic Differentiation Only
In clinical practice, the only approved growth factor alternative
to BMP2 is BMP7 (or OP-1; Stryker, Kalamazoo, MI, http://www.
stryker.com); however, BMP7 is also known to have proadipo-
genic effects [36, 37]. In contrast, NELL-1 is a growth factor in
preclinical development that has potent pro-osteogenic effects
in small and large mammalian models (reviewed in [38]) and has
been recently described to have antiadipogenic effects [26].
NELL-1 was next added to hSVF- or hPSC-laden intramuscular
implants (see supplemental online Table 5 for treatment
groups). At 4 weeks postimplantation, hPSC-treated implants
again showed increased bone formation in comparison with
hSVF, as shown by CT reconstructions (Fig. 5A, 5B) and quantifi-
cation (Fig. 5C, 5D). The addition of NELL-1 led to a significant
increase in BV and BMD among hPSC-treated implants (Fig. 5C,
5D, far right column). Histologic and histomorphometric analysis
revealed similar findings between treatment groups (Fig. 5E–
5H). Bone chips were noted to be closer together among hPSC-
treated or hPSC  NELL-1-treated implants (Fig. 5E, 5F). Histo-
morphometric calculations of bone area and bone area/tissue
area confirmed these observations (Fig. 5G, 5H). A significant
increase in both parameters was observed between hPSC-
treated and hSVF-treated implants. Moreover, hPSC NELL-1 led
Figure 6. Human white adipose tissue houses distinct pericyte and adventitial cell populations, which together represent perivascular stem
cells (PSCs). (A, B): After exclusion of DAPI dead cells (A) and CD45 hematopoietic cells (B), two PSC populations were isolated with
differential expression of CD34 and CD146. (C): Distinct CD34CD146 adventitial cells and CD34CD146 pericytes were obtained and
combined for in vivo implantation. (D): The relative numbers of pericytes and adventitial cells are depicted as a fraction of the total DAPI SVF
cells. Pericytes and adventitial cells make up approximately 17.1% and 22.5%, respectively. PSCs then represent on average 39.6% of total
viable cells. Abbreviations: DAPI, 4,6-diamidino-2-phenylindole; FSC, forward scatter; SSC, side scatter; SVF, stromal vascular fraction.
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to a significant increase over hPSC treatment alone. Unlike BMP2,
minimal lipid was observed among NELL-1-treated samples.
DISCUSSION
Perivascular Cells as a Purified Stem Cell Source
For the first time, we have shown that a purified population of
adipose-derived stem cells (hPSCs) is superior to hSVF for bone
tissue regeneration. We have shown this in terms of potency
(increased bone formation over unsorted hSVF), identity, and
purity (defined cell surface markers yielding an MSC population
of increased homogeneity without extraneous materials and
other cell lineages, such as hematopoietic and endothelial). In
theory, hPSCs would also demonstrate improved potency over
hSVF, as a defined and homogeneous cell populationwould have
more predictable in vivo outcomes than a nonhomogeneous
mixture. Moreover, hPSCs are an attractive cell source, as they
are plentiful within adipose tissue (on average constituting
40% of total viable hSVF). In this regard, even those patients
with minimal excess body fat could donate autologous fat tissue
for hPSC harvest. Moreover, sufficient quantities of hPSCs could
be harvested without the need for time-consuming and costly in
vitro expansion. Avoidance of in vitro expansion also reduces the
risk of immunogenicity, infection, and genetic instability [12, 13].
Mechanisms of hPSC Improved Osteogenicity
Although hPSCs showed improved bone formation in compari-
son with hSVF cells across all experiments and all parameters,
the underlying mechanism by which hPSCs produce higher bone
formation is only partially elucidated. One explanation is that
hSVF simply contains fewer MSCs than a purified hPSC popula-
tion. However, our experiments refute this hypothesis. For ex-
ample, adding hSVF cells at a 10:1 ratio in comparisonwith hPSCs
still led to inferior bone formation (supplemental online Fig. 1).
Another possible explanation is that within hSVF there exists a
differentiation-inhibiting cell type. In this regard, endothelial
cells have been described to negatively regulate the differentia-
tion of MSCs, such as ASCs or BMSCs [39, 40]. For instance, hu-
man endothelial cells inhibit BMSC differentiation into mature
osteoblasts by interfering with Osterix expression [40]. With this
evidence inmind, hPSCs (which are CD31)may showenhanced
bone formation in part by elimination of the endothelial cell
component. Finally, the trophic effect of hPSCs should not be
overlooked. Perivascular cells have been observed to secrete
high levels of pro-osteogenic, provasculogenic growth factors,
such as vascular endothelial growth factor, fibroblast growth fac-
tor 2, and epidermal growth factor [24]. PSCs may induce robust
in vivo bone formation largely through trophic effects via para-
crine induction of vasculogenesis and osteogenesis.
Choice of Osteoinductive Growth Factor
Themarriage of an osteocompetent cell sourcewith osteoinduc-
tive growth factors is a logical union for skeletal tissue engineer-
ing. We examined both BMP2 and NELL-1 as candidate growth
factors. BMP2 (INFUSE Bone Graft) is the main FDA-approved
osteoinductive factor, but it has significant undesirable side ef-
fects, including life-threatening cervical swelling [41], osteoclast
activation [42], adipogenic differentiation [43], and bone cyst
formation [44, 45]. In particular to our study, we found that
BMP2 induced a massive adipogenic response and showed poor
bone quality (reduced bone mineral density) (Fig. 4). This is in line
with BMP2’s known effects in enhancing the transcription and ac-
tivity of peroxisome proliferator-activated receptor , the main
transcription factor regulating adipocyte lineage commitment [46,
47]. In contrast,NELL-1 showedamoreosteospecific response,with
noapparent inductionof adipogenesis (Fig. 5).Our laboratory’s pre-
vious publications show that exogenous NELL-1 induces significant
bone formation in such models as critical sized rat calvarial defects
[45]; rat femoral segmental defects [48]; and spinal fusion in rat [30,
49], sheep [50], and nonhuman primate models (manuscript in
preparation). The pro-osteogenic effect of NELL-1was also recently
reportedusingpericytesderived fromfetalpancreas inan intramus-
cular ectopic bone environment [32].
CONCLUSION
In summary, these data show that hPSCs are readily obtainable
from human lipoaspirate. Moreover, hPSCs are able to form
bone in vivo without the need for predifferentiation. Next, un-
cultured hPSCswere observed to be superior to patient-matched
hSVF with respect to the quantity and quality of bone formation.
Finally, through a series of in vivo experiments, we have opti-
mized a combination product for local bone formation by deliv-
ering autologous, purified adult hPSCs and an osteoinductive
protein (NELL-1) on an acellular allograft bone scaffold.
PSCs not only show improved efficacy in bone formation rela-
tive to sample-matched hSVF but also show improvements in other
parameters for FDA approval. These include enhanced purity and
identity (PSCs are anMSC population containing no hematopoietic
stem cells, endothelial cells, or nonviable cells), and potency (as a
more defined cell population, hPSCs will likely have reduced vari-
ability in effect as compared with hSVF). In fact, the intramuscular
implantation assay describedmay well serve as an easily replicable
assay for hPSCpotency in bone formation. Excitingly, recent studies
have already demonstrated the utility of perivascular stem cells for
regeneration of disparate tissue types, including skeletal muscle
[51], lung [52], and even myocardium [25]. Further studies will ex-
tendour findingsandapply therobustosteogenicpotentialofhPSCs
to the healing of bone defects.
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